State-of-the-art mechanisms of intracochlear drug delivery

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 16, Issue 5, 2008, Pages 472-477

  Borkholder, David A ^a,b,c  

^a ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Kate Gleason College of Engineering   (United States)

Author keywords

Gene therapy; Inner ear drug delivery; intracochlear; nanoparticle; Transtympanic

Indexed keywords

CORTICOSTEROID; GENTAMICIN; METHYLPREDNISOLONE; NANOPARTICLE;

COCHLEA PROSTHESIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HUMAN; INNER EAR; MENIERE DISEASE; MOLECULAR THERAPY; NANOTECHNOLOGY; NONHUMAN; PERCEPTION DEAFNESS; PRIORITY JOURNAL; REVIEW; VESTIBULAR DISORDER; ANIMAL; COCHLEA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EARDRUM; GENE THERAPY; INTRALESIONAL DRUG ADMINISTRATION; METHODOLOGY; SENSITIVITY AND SPECIFICITY; SUDDEN DEAFNESS;

ADRENAL CORTEX HORMONES; ANIMALS; COCHLEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENTAMICINS; HEARING LOSS, SUDDEN; HUMANS; INJECTIONS, INTRALESIONAL; MENIERE DISEASE; NANOPARTICLES; SENSITIVITY AND SPECIFICITY; TYMPANIC MEMBRANE;

EID: 58149354604     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32830e20db     Document Type: Review

References (78)

1. Jackson LE, Silverstein H. Chemical perfusion of the inner ear. Otolaryngol Clin North Am 2002; 35:639-653.
2. Light JP, Silverstein H. Transtympanic perfusion: indications and limitations. Curr Opin Otolaryngol Head Neck Surg 2004; 12:378-383.
3. Hoffer ME, Balough BJ, Gottshall KR. Delivery of drugs to the inner ear. Curr Opin Otolaryngol Head Neck Surg 2006; 14:329-331.
4. Darlington CL, Smith PF. Drug treatments for tinnitus. Prog Brain Res 2007; 166:249-262.
5. Plontke SKR, Wood AW, Salt AN. Analysis of gentamicin kinetics in fluids of the inner ear with round window administration. Otol Neurotol 2002; 23:967-974.
6. Hargunani CA, Kempton JB, DeGagne JM, et al. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol 2006; 27:564-569.
7. Plontke SK, Salt AN. Simulation of application strategies for local drug delivery to the inner ear. ORL J Otorhinolaryngol Relat Spec 2006; 68:386-392.
8. Plontke SK, Mynatt R, Gill RM, et al. Concentration gradient along the scala tympani after local application of gentamicin to the round window membrane. Laryngoscope 2007; 117:1191-1198.
9. Plontke SK, Siedow N, Wegener R, et al. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurootol 2007; 12:37-48.
10. Plontke SK, Biegner T, Kammerer B, et al. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008; 29:401-406.
11. Olivius P, Alexandrov L, Miller JM, et al. A model for implanting neuronal tissue into the cochlea. Brain Res Brain Res Protoc 2004; 12:152-156.
12. Patel NP, Mhatre AN, Lalwani AK. Biological therapy for the inner ear. Expert Opin Biol Ther 2004; 4:1811-1819.
13. Staecker H, Brough DE, Praetorius M, et al. Drug delivery to the inner ear using gene therapy. Otolaryngol Clin North Am 2004; 37:1091-1108.
14. NakagawaT, Ito J. Cell therapy for inner ear diseases. Curr Pharm Des 2005; 11:1203-1207.
15. Tang LS, Montemayor C, Pereira FA. Sensorineural hearing loss: potential therapies and gene targets for drug development. IUBMB Life 2006; 58:525-530.
16. Richardson RT, Noushi F, O'Leary S. Inner ear therapy for neural preservation. Audiol Neurootol 2006; 11:343-356.
17. Iwai K, Nakagawa T, Endo T, et al. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope 2006; 116:529-533.
18. Lee KY, NakagawaT, OkanoT, et al. Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel. Otol Neurotol 2007; 28:976-981.
19. Lalwani AK, Jero J, Mhatre AN. Current issues in cochlear gene transfer. Audiol Neurootol 2002; 7:146-151.
20. Izumikawa M, MinodaR, Kawamoto K, et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 2005; 11:271-276.
21. Staecker H, Praetorius M, Baker K, et al. Vestibular hair cell regeneration and restoration of balance function induced by math1 gene transfer. Otol Neurotol 2007; 28:223-231.
22. Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007; 28:1124-1130.
23. Plontke SK, Zimmermann R, Zenner H-P, et al. Technical note on micro-catheter implantation for local inner ear drug delivery: surgical technique and safety aspects. Otol Neurotol 2006; 27:912-917.
24. Van WijkF, Staecker H, Keithley E, et al. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol 2006; 11:357-365.
25. Hoffer ME, Balough BJ,Gottshall KR, et al. Sustained-release devices in inner ear medical therapy. Otolaryngol Clin North Am 2004; 37:1053-1060.
26. Hoffer ME, Allen K, Kopke RD, et al. Transtympanic versus sustained-release administration of gentamicin: kinetics, morphology, and function. Laryngoscope 2001; 111:1343-1357.
27. Wagner N,Caye-Thomasen P, Laurell G, et al. Cochlear hair cell loss in single-dose versus continuous round window administration of gentamicin. Acta Otolaryngol 2005; 125:340-345.
28. Hoffmann KK, Silverstein H. Inner ear perfusion: indications and applications. Curr Opin Otolaryngol Head Neck Surg 2003; 11:334-339.
29. Roehm P, Hoffer M, Balaban CD. Gentamicin uptake in the chinchilla inner ear. Hear Res 2007; 230:43-52.
30. Hashimoto Y, IwasakiS, MizutaK, et al. Pattern of cochlear damage caused by short-term kanamycin application using the round window microcatheter method. Acta Otolaryngol 2007; 127:116-121.
31. Coleman JKM, Littlesunday C, Jackson R, et al. AM-111 protects against permanent hearing loss from impulse noise trauma. Hear Res 2007; 226:70-78.
32. Nakagawa T, Ito J. Drug delivery systems for the treatment of sensorineural hearing loss. Acta Otolaryngol Suppl 2007; 557:30-35.
33. Sheppard WM, Wanamaker HH, Pack A, et al. Direct round window application of gentamicin with varying delivery vehicles: a comparison of ototoxicity. Otolaryngol Head Neck Surg 2004; 131:890-896.
34. Paulson DP, Abuzeid W, Jiang H, et al. A novel controlled local drug delivery system for inner ear disease. Laryngoscope 2008; 118:706-711.
35. TamuraT, KitaT, NakagawaT, et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope 2005; 115:2000-2005.
36. Ge X, Jackson RL, Liu J, et al. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol Head Neck Surg 2007; 137:619-623.
37. PraetoriusM,BrunnerC,LehnertB, et al.Transsynapticdeliveryofnanoparticles to the central auditory nervous system. Acta Otolaryngol 2007; 127:486-490.
38. Zou J, Saulnier P, PerrierT, et al. Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. J Biomed Mater Res B Appl Biomater 2008 [Epub ahead of print].
39. Staecker H, Li D, O'Malley BW, et al. Gene expression in the mammalian cochlea: a study of multiple vector systems. Acta Otolaryngol 2001; 121:157-163.
40. IshimotoS-i, Kawamoto K, Kanzaki S, et al. Gene transfer into supporting cells of the organ of Corti. Hear Res 2002; 173:187-197.
41. Yamasoba T, Yagi M, Roessler BJ, et al. Inner ear transgene expression after adenoviral vector inoculation in the endolymphatic sac. Hum Gene Ther 1999; 10:769-774.
42. Kawamoto K, Oh SH, Kanzaki S, et al. The functional and structural outcome of inner ear gene transfer via the vestibular and cochlear fluids in mice. Mol Ther 2001; 4:575-585.
43. Suzuki M, Yagi M, Brown JN, et al. Effect of transgenic GDNF expression on gentamicin-induced cochlear and vestibular toxicity. Gene Ther 2000; 7:1 046-1054.
44. Bowers WJ, Chen X, Guo H, et al. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. MolTher 2002; 6:12-18.
45. Kingma GG, Miller JM, Myers MW. Chronic drug infusion into the scala tympani of the guinea pig cochlea. J Neurosci Methods 1992; 45:127-134.
46. Brown JN, Miller JM, Altschuler RA, et al. Osmotic pump implant for chronic infusion of drugs into the inner ear. Hear Res 1993; 70:167-172.
47. Schindler RA, Gladstone HB, Scott N, et al. Enhanced preservation of the auditory nerve following cochlear perfusion with nerve growth factors. Am J Otol 1995; 16:304-309.
48. Ernfors P, Duan ML, ElShamy WM, et al. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nat Med 1996; 2:463-467.
49. Lalwani AK, Han JJ, Walsh BJ, et al. Green fluorescent protein as a reporter for gene transfer studies in the cochlea. Hear Res 1997; 114:139-147.
50. Staecker H, Gabaizadeh R, Federoff H, et al. Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss. Otolaryngol Head Neck Surg 1998; 119:7-13.
51. Carvalho GJ, Lalwani AK. The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. Am J Otol 1999; 20:87-90.
52. Prieskorn DM, Miller JM. Technical report: chronic and acute intracochlear infusion in rodents. Hear Res 2000; 140:212-215.
53. Luebke AE, Steiger JD, Hodges BL, et al.A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function. GeneTher 2001; 8:789-794.
54. Wang J, Dib M, Lenoir M, et al. Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience 2002; 111:635-648.
55. Wang J, Van De Water TR, Bonny C, et al.A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 2003; 23:8596-8607.
56. Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 2003; 45:380-393.
57. Horiike O, Shimogori H, Ikeda T, et al. Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig. Eur J Pharmacol 2003; 464:75-78.
58. Kawamoto K, Sha SH, Minoda R, et al. Antioxidant gene therapy can protect hearing and hair cells from ototoxicity. Mol Ther 2004; 9:173-181.
59. Takemoto T, Sugahara K, Okuda T, et al. The clinical free radical scavenger, edaravone, protects cochlear hair cells from acoustic trauma. Eur J Pharmacol 2004; 487:113-116.
60. McGuinness SL, Shepherd RK. Exogenous BDNF rescues rat spiral ganglion neurons in vivo. Otol Neurotol 2005; 26:1064-1072.
61. Chen Z, Mikulec AA, McKenna MJ, et al. A method for intracochlear drug delivery in the mouse. J Neurosci Methods 2006; 150:67-73.
62. Wang J, Pignol B, Chabrier P-E, et al. A novel dual inhibitor of calpains and lipid peroxidation (BN82270) rescues the cochlea from sound trauma. Neuropharmacology 2007; 52:1426-1437.
63. Eshraghi AA, Adil E, He J, et al. Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otol Neurotol 2007; 28:842-849.
64. Miller JM, Le Prell CG, Prieskorn DM, et al. Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: effects of brain-derived neurotrophic factor and fibroblast growth factor. J Neurosci Res 2007; 85:1959-1969.
65. Shepherd RK, Xu J. A multichannel scala tympani electrode array incorporating a drug delivery system for chronic intracochlear infusion. Hear Res 2002; 172:92-98.
66. Rebscher SJ, Hetherington AM, Snyder RL, et al. Design and fabrication of multichannel cochlear implants for animal research. J Neurosci Methods 2007; 166:1-12.
67. Paasche G, Bogel L, Leinung M, et al. Substance distribution in a cochlea model using different pump rates for cochlear implant drug delivery electrode prototypes. Hear Res 2006; 212:74-82.
68. Stöver T, Paasche G, Lenarz T, et al. Development of a drug delivery device: using the femtosecond laser to modify cochlear implant electrodes. Cochlear Implants Int 2007; 8:38-52.
69. Kawamoto K, Kanzaki S, Yagi M, et al. Gene-based therapy for inner ear disease. Noise Health 2001; 3:37-47.
70. Nakaizumi T, Kawamoto K, Minoda R, et al. Adenovirus-mediated expression of brain-derived neurotrophic factor protects spiral ganglion neurons from ototoxic damage. Audiol Neurootol 2004; 9:135-143.
71. Liu Y, OkadaT, Shimazaki K, et al. Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea. Mol Ther 2008; 16:474-480.
72. Kawamoto K, IshimotoS, Minoda R, et al. Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci 2003; 23:4395-4400.
73. Praetorius M, Baker K, Brough DE, et al. Pharmacodynamics of adenovector distribution within the inner ear tissues of the mouse. Hearing Res 2007; 227:53-58.
74. Liu Y, Okada T, Sheykholeslami K, et al. Specific and efficient transduction of Cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. Mol Ther 2005; 12:725-733.
75. Salt AN. Pharmacokinetics of drug entry into cochlear fluids. Volta Rev 2005; 105:277-298.
76. Rask-Andersen H, Schrott-Fischer A, Pfaller K, Glueckert R. Perilymph/ modiolar communication routes in the human cochlea. Ear Hear 2006; 27:457-465.
77. Stöver T, Yagi M, Raphael Y. Transduction of the contralateral ear after adenovirus-mediated cochlear gene transfer. Gene Ther 2000; 7:377-383.
78. Chen Z, Kujawa SG, McKenna MJ, et al. Inner ear drug delivery via a reciprocating perfusion system in the guinea pig. J Control Release 2005; 110:1-19.